About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Cancer Immunology, Immunotherapy
›
Top Articles
Cancer Immunology, Immunotherapy
Oncology
,
Biology
,
Immunology
7.4
(top 1%)
Impact Factor
7.8
(top 1%)
extended IF
127
(top 2%)
H-Index
4K
authors
6K
papers
152.3K
citations
5.2K
citing journals
58.1K
citing authors
Most Cited Articles of Cancer Immunology, Immunotherapy
Title
Year
Citations
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
2009
949
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
2007
944
An immune-active tumor microenvironment favors clinical response to ipilimumab
2012
562
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
2005
490
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
2011
446
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
2005
422
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
2010
421
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
1993
414
A listing of human tumor antigens recognized by T cells: March 2004 update
2005
378
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
2009
377
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
2014
367
A listing of human tumor antigens recognized by T cells
2001
366
Apoptosis pathways in cancer and cancer therapy
2004
363
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
2007
345
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
2000
333
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion
2007
332
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
2014
328
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
2009
309
Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes
2006
300
Role of immature myeloid cells in mechanisms of immune evasion in cancer
2006
294
Derangement of immune responses by myeloid suppressor cells
2004
294
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
2009
292
Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
2012
266
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
2013
265
Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies
2007
265
previous
2009
2010
2011
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.